88 related articles for article (PubMed ID: 20375244)
1. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.
Meng JZ; Dong YJ; Huang H; Li S; Zhong Y; Liu SL; Wang YD
Clin Vaccine Immunol; 2010 Jun; 17(6):889-94. PubMed ID: 20375244
[TBL] [Abstract][Full Text] [Related]
2. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.
Susumu S; Nagata Y; Ito S; Matsuo M; Valmori D; Yui K; Udono H; Kanematsu T
Cancer Sci; 2008 Jan; 99(1):107-12. PubMed ID: 17991294
[TBL] [Abstract][Full Text] [Related]
3. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
Gnjatic S; Jäger E; Chen W; Altorki NK; Matsuo M; Lee SY; Chen Q; Nagata Y; Atanackovic D; Chen YT; Ritter G; Cebon J; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11813-8. PubMed ID: 12186971
[TBL] [Abstract][Full Text] [Related]
4. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
[TBL] [Abstract][Full Text] [Related]
5. Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.
Dos Santos LI; Galvão-Filho B; de Faria PC; Junqueira C; Dutra MS; Teixeira SM; Rodrigues MM; Ritter G; Bannard O; Fearon DT; Antonelli LR; Gazzinelli RT
Cancer Immunol Immunother; 2015 Mar; 64(3):311-23. PubMed ID: 25403749
[TBL] [Abstract][Full Text] [Related]
6. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
[TBL] [Abstract][Full Text] [Related]
7. Multiplex genetic manipulations in Clostridium butyricum and Clostridium sporogenes to secrete recombinant antigen proteins for oral-spore vaccination.
Zhang Y; Bailey TS; Hittmeyer P; Dubois LJ; Theys J; Lambin P
Microb Cell Fact; 2024 Apr; 23(1):119. PubMed ID: 38659027
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
Valmori D; Souleimanian NE; Tosello V; Bhardwaj N; Adams S; O'Neill D; Pavlick A; Escalon JB; Cruz CM; Angiulli A; Angiulli F; Mears G; Vogel SM; Pan L; Jungbluth AA; Hoffmann EW; Venhaus R; Ritter G; Old LJ; Ayyoub M
Proc Natl Acad Sci U S A; 2007 May; 104(21):8947-52. PubMed ID: 17517626
[TBL] [Abstract][Full Text] [Related]
9. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
Anderson LD; Cook DR; Yamamoto TN; Berger C; Maloney DG; Riddell SR
Cancer Immunol Immunother; 2011 Jul; 60(7):985-97. PubMed ID: 21461886
[TBL] [Abstract][Full Text] [Related]
10. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Davis ID; Chen W; Jackson H; Parente P; Shackleton M; Hopkins W; Chen Q; Dimopoulos N; Luke T; Murphy R; Scott AM; Maraskovsky E; McArthur G; MacGregor D; Sturrock S; Tai TY; Green S; Cuthbertson A; Maher D; Miloradovic L; Mitchell SV; Ritter G; Jungbluth AA; Chen YT; Gnjatic S; Hoffman EW; Old LJ; Cebon JS
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10697-702. PubMed ID: 15252201
[TBL] [Abstract][Full Text] [Related]
11. Multi-antigen DNA vaccine delivered by polyethylenimine and Salmonella enterica in neuroblastoma mouse model.
Stegantseva MV; Shinkevich VA; Tumar EM; Meleshko AN
Cancer Immunol Immunother; 2020 Dec; 69(12):2613-2622. PubMed ID: 32594197
[TBL] [Abstract][Full Text] [Related]
12. Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma.
Zhu X; Zhou P; Cai J; Yang G; Liang S; Ren D
Cancer Sci; 2010 Dec; 101(12):2621-8. PubMed ID: 20880334
[TBL] [Abstract][Full Text] [Related]
13. Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.
Gedye C; Quirk J; Browning J; Svobodová S; John T; Sluka P; Dunbar PR; Corbeil D; Cebon J; Davis ID
Cancer Immunol Immunother; 2009 Oct; 58(10):1635-46. PubMed ID: 19221743
[TBL] [Abstract][Full Text] [Related]
14. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.
Sun Z; Lethé B; Zhang Y; Russo V; Colau D; Stroobant V; Boon T; van der Bruggen P
Cancer Immunol Immunother; 2006 Jun; 55(6):644-52. PubMed ID: 16187088
[TBL] [Abstract][Full Text] [Related]
15. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.
Romero P; Cerottini JC; Speiser DE
Cancer Immunol Immunother; 2004 Mar; 53(3):249-55. PubMed ID: 14704832
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.
Mussai F; Egan S; Hunter S; Webber H; Fisher J; Wheat R; McConville C; Sbirkov Y; Wheeler K; Bendle G; Petrie K; Anderson J; Chesler L; De Santo C
Cancer Res; 2015 Aug; 75(15):3043-53. PubMed ID: 26054597
[TBL] [Abstract][Full Text] [Related]
17. Engineering Probiotic E. coli Nissle 1917 for Release of Therapeutic Nanobodies.
Gurbatri C; Danino T
Methods Mol Biol; 2024; 2748():289-305. PubMed ID: 38070121
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bivalent
Li Y; Zhu X; You J; Zhang B; Huang X; Jin C
Heliyon; 2022 Oct; 8(10):e10775. PubMed ID: 36212004
[TBL] [Abstract][Full Text] [Related]
19. Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.
Gupta KH; Nowicki C; Giurini EF; Marzo AL; Zloza A
Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960243
[TBL] [Abstract][Full Text] [Related]
20. Innovative Approaches of Engineering Tumor-Targeting Bacteria with Different Therapeutic Payloads to Fight Cancer: A Smart Strategy of Disease Management.
Allemailem KS
Int J Nanomedicine; 2021; 16():8159-8184. PubMed ID: 34938075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
